Scarica l'app Stockscreener
12.67
0.55%
-0.07
Pre-mercato:
12.69
0.02
+0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Biohaven Ltd Borsa (BHVN) Ultime notizie
Aug Action: Is First Merchants Corporation attractive for institutional investorsEarnings Risk Summary & Real-Time Volume Triggers - baoquankhu1.vn
Jim Cramer on Biohaven: “The Stock Seems Very Low to Me” - MSN
Assessing Biohaven (BHVN) Valuation After A Sharp Momentum Rebound - Yahoo Finance
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
This Albemarle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
RBC Capital Upgrades Biohaven (BHVN) - Nasdaq
BHVN Upgraded by RBC Capital: New Price Target of $22 | BHVN Sto - GuruFocus
RBC Upgrades Biohaven to Outperform From Sector Perform, Boosts Price Target to $22 From $9, Keeps Speculative Risk - marketscreener.com
Biohaven stock rating upgraded by RBC Capital on promising CNS data - Investing.com South Africa
(BHVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Biohaven (BHVN) Is Up 15.6% After Showcasing MoDE and TRAP Degrader Data in Autoimmune Diseases - Sahm
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly - BioSpace
Assessing Biohaven (BHVN) Valuation After Positive MoDE And TRAP Degrader Clinical Updates - Sahm
Pomerantz To Lead Biohaven Investors' FDA Approval Suit - Law360
Biohaven (NYSE:BHVN) Stock Price Up 8%Still a Buy? - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data - Intellectia AI
Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know - Benzinga
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Can Biohaven Ltd. deliver alphaMarket Weekly Review & Low Risk High Reward Ideas - bollywoodhelpline.com
Biohaven Ltd. (BHVN) Investor Outlook: Navigating Opportunities with a 68% Upside Potential - DirectorsTalk Interviews
Biohaven (NYSE:BHVN) Shares Down 6.3%Here's Why - MarketBeat
Biohaven (BHVN) Is Up 19.2% After Early Success With Selective Antibody Degraders In Kidney, Thyroid Diseases - simplywall.st
Biohaven stock maintains Outperform rating at Baird on promising IgAN data - Investing.com
Biohaven stock maintains Outperform rating at Baird on promising IgAN data By Investing.com - Investing.com South Africa
Biohaven highlights degrader platforms in new investor presentation - TipRanks
Biohaven Ltd Announces Investor Presentation on January 12, 2026 - TradingView
Biohaven reports early patient data from protein degrader programs - StreetInsider
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - PR Newswire
Aug Update: Is Biohaven Ltd stock oversold or undervaluedJuly 2025 Volume & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Biohaven Ltd. (BHVN) upgraded to buy: Here's what you should know - MSN
(BHVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jobs Data: Why Biohaven Ltd stock attracts global investorsWeekly Stock Recap & AI Based Buy/Sell Signal Reports - moha.gov.vn
Volatility Watch: Why Biohaven Ltd stock attracts global investorsEarnings Growth Summary & Real-Time Volume Triggers - moha.gov.vn
Will Biohaven Ltd. stock continue dividend increasesQuarterly Profit Review & Verified Chart Pattern Signals - Улправда
Is Biohaven Ltd. stock overvalued by current metricsMarket Risk Report & AI Forecast for Swing Trade Picks - Улправда
Will Biohaven Ltd. stock recover faster than peersTrade Volume Report & Daily Risk Controlled Trade Plans - ulpravda.ru
Aug Final Week: Is Biohaven Ltd. stock oversold or undervaluedQuarterly Portfolio Report & Long-Term Growth Stock Strategies - Улправда
Is Biohaven Ltd. stock oversold or undervalued2025 Buyback Activity & Low Drawdown Investment Ideas - Улправда
Biohaven (NYSE:BHVN) Shares Up 11.9%Here's Why - MarketBeat
Biohaven expects to raise $125M in stock sale - Hartford Business Journal
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Co - GuruFocus
Biohaven Announces $125 Million Targeted Equity Financing - TipRanks
Biohaven Ltd. Announces $125 Million Share Sale - TradingView — Track All Markets
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a Potential 96% Upside in the Biotech Sector - DirectorsTalk Interviews
Why Biohaven Ltd. Common Shares stock is a strong analyst pick2026 world cup usa national team round of 32 star players transition play knockout prediction preview - ulpravda.ru
Morgan Stanley Lowers Price Target for Biohaven (BHVN) to $21 | - GuruFocus
Morgan Stanley Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price - MarketBeat
Stock market today: Dow Jones, S&P 500 futures slip after Christmas Day—Nvidia, Sobr Safe, Biohaven in focus - MSN
Biohaven Ltd. (NYSE:BHVN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Biohaven (NYSE:BHVN) Trading Down 8%Here's What Happened - MarketBeat
Biohaven (BHVN) Is Down 6.1% After Ending BHV-7000 Depression Trial To Refocus On Epilepsy And Obesity - simplywall.st
The Bull Case For Biohaven (BHVN) Could Change Following BHV-7000 MDD Trial Halt And R&D Pivot - Yahoo Finance
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):